Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Recommendation of “Hold” by Brokerages

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have been given an average recommendation of “Hold” by the six analysts that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating. The average 12-month price objective among analysts that have covered the stock in the last year is $2.32.

Separately, StockNews.com started coverage on Cara Therapeutics in a report on Saturday. They set a “sell” rating for the company.

Cara Therapeutics Price Performance

CARA stock opened at $0.26 on Wednesday. Cara Therapeutics has a one year low of $0.24 and a one year high of $1.65. The stock has a market cap of $13.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.70. The company has a fifty day moving average price of $0.31 and a two-hundred day moving average price of $0.48.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. Research analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after acquiring an additional 120,660 shares during the period. Disciplined Growth Investors Inc. MN owned approximately 3.54% of Cara Therapeutics worth $499,000 as of its most recent filing with the Securities and Exchange Commission. 44.66% of the stock is owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.